/YDES
YDES Stock - YD Bio Limited Ordinary Shares
Healthcare|BiotechnologyNASDAQ
$12.38+9.22%
+$1.04 (+9.22%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $13.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for YDES
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.26 – $12.50
TARGET (TP)$14.24
STOP LOSS$11.39
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.12
52W High$25.00
52W Low$5.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $510,360 | $350,131 | N/A | N/A | N/A |
| Gross Profit | $155,356 | $153,445 | N/A | N/A | N/A |
| Gross Margin | 30.4% | 43.8% | N/A | N/A | N/A |
| Operating Income | $-1,461,930 | $-9,847 | $-2,323,153 | $-1,722,364 | $-344,223 |
| Net Income | $-1,411,559 | $13,560 | $3.79M | $8.70M | $-2,537,690 |
| Net Margin | -276.6% | 3.9% | N/A | N/A | N/A |
| EPS | $-0.56 | $0.00 | $0.41 | $0.59 | $-0.17 |
Company Overview
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
YDESLoading earnings data...
Latest News
YD Bio Announces Latest Plans For New Sites, U.S. Operations Center In California
📈 PositiveBenzinga•Dec 16, 2025, 02:05 PM
YD Bio shares are trading higher after the company announced it obtained 510(k) clearance and OTC monograph compliance. The company announced that it, along with 3D Global Biotech, is planning a small clinical trial in Taiwan to evaluate dry eye disease.
📈 PositiveBenzinga•Nov 24, 2025, 08:31 PM
Reported Earlier: YD Bio Through Its Partner 3D Global Biotech, Announces Exovisse Contact Lenses Has Obtained FDA 510(k) Clearance As A Class II Medical Device, Enabling Legal Marketing In The U.S.; Its Exovisse Artificial Tears Have Been Developed In Compliance With The FDA OTC Final Monograph M018
📈 PositiveBenzinga•Nov 24, 2025, 08:19 PM
YD Bio Announces Its Support For The Global Commercialization Of Okaidx, A Research-Use-Only Blood Test For Post-Treatment Breast Cancer Monitoring
📈 PositiveBenzinga•Nov 5, 2025, 01:35 PM
YD Bio Announces CAP Accreditation Of EG Biomed's CLIA-Certified Laboratory, Advancing U.S. Clinical Testing Capabilities
📈 PositiveBenzinga•Oct 10, 2025, 12:39 PM
Reported Earlier: YD Bio COO May Tsai Resigns For Health Reasons, Effective As Of September 24, 2025
➖ NeutralBenzinga•Sep 26, 2025, 05:34 PM
YD Bio Limited shares are trading higher following the closing of its SPAC merger and listing on the Nasdaq.
📈 PositiveBenzinga•Aug 29, 2025, 02:30 PM
Frequently Asked Questions about YDES
What is YDES's current stock price?
YD Bio Limited Ordinary Shares (YDES) is currently trading at $12.38 per share. The stock has moved +9.22% today.
What is the analyst price target for YDES?
No analyst price targets are currently available for this stock.
What sector is YD Bio Limited Ordinary Shares in?
YD Bio Limited Ordinary Shares operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is YDES's market cap?
YD Bio Limited Ordinary Shares has a market capitalization of $0.87 billion, making it a small-cap company.
Does YDES pay dividends?
No, YD Bio Limited Ordinary Shares does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBTX
BlackRock Technology and Private Equity Term Trust
$6.72
Mkt Cap: $0.8B
DAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
GLUE
Monte Rosa Therapeutics, Inc.
$15.54
Mkt Cap: $1.0B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
TBPH
Theravance Biopharma, Inc.
$18.79
Mkt Cap: $1.0B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to YDES for comparison